Shares in Bavarian Nordic A/S dropped more than 3 percent Tuesday on news that the company is planning to raise DKK250 million (US$50.6 million) to DKK300 million early in the new year. (BioWorld International) Read More
No Abstract BioWorld International CorrespondentWilex AG delayed completion of a capital increase because of the early arrival of positive preliminary data from a Phase III trial of its diagnostic antibody Redectane, which is in development for presurgical detection of clear cell renal cell carcinoma, the most common form of kidney cancer. Read More
